A.M.M. Eggermont - Concepedia

Author

A.M.M. Eggermont

Rotterdam University of Applied Sciences

Also Known As

A Eggermont, A M Eggermont, A M M Eggermont, A. Eggermont, A. M. Eggermont, A. M. M. EGGERMONT, A. M. M. Eggermont, A.M.M Eggermont, A.M.M. Eggermont, AMM Eggermont

130

Publications

Citations

H-Index

Concepts

All Affiliations

Rotterdam University of Applied Sciences Erasmus MC Cancer Institute Radboud University Nijmegen The Netherlands Cancer Institute European Organisation for Research and Treatment of Cancer

About

A.M.M. Eggermont is an author at Rotterdam University of Applied Sciences specializing in medicine, immunology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	32	1.4K
2	Health Sciences	5	5	153
3	Diagnostic Sciences	2	2	210
4	Public Health	1	1	140
5	Cell Biology	1	1	30

A.M.M. Eggermont

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Final results of the EORTC 18871/DKG 80-1 randomised phase III trial Ulrich R. Kleeberg, Stefan Suciu, E.‐B. Bröcker, European Journal of Cancer Clinical TrialsRandomized Controlled TrialEortc 18871/DkgDrug TrialMedicine	2003	236
Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion Johannes H. W. de Wilt, Timo L.M. ten Hagen, Gert De Boeck, British Journal of Cancer	2000	204
Total Pelvic Exenteration for Primary and Recurrent Malignancies Floris Ferenschild, Maarten Vermaas, Cornelis Verhoef, World Journal of Surgery	2009	188
TNF- α augments intratumoural concentrations of doxorubicin in TNF- α -based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects A.H. van der Veen, Johannes H. W. de Wilt, A.M.M. Eggermont, British Journal of Cancer	2000	150
Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials K. Wheatley, Natalie Ives, A.M.M. Eggermont, Journal of Clinical Oncology Surgical OncologyIndividual Patient DataDermatologyAdjuvant TherapyOncology	2007	140
Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats Johannes H.W. de Wilt, Eric R. Manusama, Sandra T. van Tiel, British Journal of Cancer	1999	114
Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study SH Goey, A.M.M. Eggermont, CJA Punt, British Journal of Cancer InflammationInterleukin 2Intrapleural AdministrationImmunologyPathology	1995	107
Aggressive angiomyxoma: multimodality treatments can avoid mutilating surgery I. J. M. Han‐Geurts, Albertus N. van Geel, Leni van Doorn, European Journal of Surgical Oncology Vascular MalformationMultimodalityThoracic SurgerySurgeryMedicine	2006	100
Cancer Patients Seeking a Second Surgical Opinion: Results of a Study on Motives, Needs, and Expectations W. A. M. Mellink, Th. Wiggers, Peter Spreeuwenberg, Journal of Clinical Oncology	2003	95
Synergistic antitumour effect of recombinant human tumour necrosis factor a with melphalan in isolated limb perfusion in the rat Eric R. Manusama, Peet Nooijen, Jeroen Stavast, British journal of surgery	1996	89

Page 1